Hansoh Pharmaceutical Group has delivered very strong share gains over the past few years, which puts a spotlight on whether the current price is supported by the cash it can generate. With fresh trial results and sentiment moving around the stock, the key issue is how those developments translate into long term cash flows.
-
Over the past 3 years, Hansoh Pharmaceutical Group has returned about 153.1%, which makes the link between the share move and its underlying cash generation especially important for anyone considering the stock today.
-
Positive Phase III data for risvutatug rezetecan in relapsed osteosarcoma may support expectations for future revenue and influence assumptions about the timing and durability of Hansoh Pharmaceutical Group's cash flows.
-
If you'd rather focus on earnings, this one's for you. See why Hansoh Pharmaceutical Group's 27.2x P/E tells a different valuation story .
For investors, the debate is whether Hansoh Pharmaceutical Group's current share price is properly aligned with the cash flows implied by its intrinsic value estimate from a Discounted Cash Flow (DCF) model.
If you want a wider lens on companies where cash generation is central to the story, compare Hansoh Pharmaceutical Group with 210 high quality undervalued stocks .
Is Hansoh Pharmaceutical Group a Bargain on Cash Flow?
The Discounted Cash Flow (DCF) approach here looks at the cash Hansoh Pharmaceutical Group is expected to generate for shareholders over time. On the latest twelve month numbers, the business produced about CN¥4.9b in free cash flow, and the model assumes that this pool of cash continues to grow rather than shrink. Under those assumptions, the DCF output suggests an intrinsic value that is substantially above the current share price of HK$35.18.
The projections step up to multi year free cash flow in the low tens of billions of CN¥, then settle into more moderate growth as the company matures in the model. Positive Phase III data for risvutatug rezetecan, and the potential for a related regulatory submission in China, help explain why the valuation model bakes in ongoing cash generation strength even though the market price has not fully followed. For readers who want to see how each assumption affects the end result, the full DCF detail is available here. Find out what Hansoh Pharmaceutical Group could be worth using our Discounted Cash Flow (DCF) estimate .
The Hansoh Pharmaceutical Group Narrative: What Would Justify Today's Price?
Narratives pick up where the DCF puzzle leaves off for Hansoh Pharmaceutical Group by spelling out which paths for growth, margins and earnings would need to play out for the shares to be worth materially more or less than today's price on Simply Wall St's Community page. Each narrative ties a specific fair value to a distinct storyline about Hansoh Pharmaceutical Group's potential catalysts and key risks, so you can track over time which version of events is actually unfolding.
A written, number driven view on Hansoh Pharmaceutical Group gives you a clear set of assumptions to test against future free cash flow and any impact from the ARTEMIS-011 risvutatug rezetecan outcome. It also creates a reference point you can revisit as new data on cash generation, margins and regulatory progress arrives, so you can judge whether the thesis is holding up or needs adjusting.
Share your own Narrative for Hansoh Pharmaceutical Group and set out the assumptions behind your valuation.
One more piece of the Hansoh Pharmaceutical Group puzzle to check first
Before you put too much weight on any valuation work for Hansoh Pharmaceutical Group, it is worth pausing on the specific risk checks that our research has flagged for this business. Take a closer look at 1 major warning sign before settling on a valuation.
This article is general in nature and was produced with the assistance of AI automation, based on data and analysis from Simply Wall St. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include 3692.HK .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
